Media
Press Releases
May 18, 2026
Lupin Receives Tentative Approval from U.S. FDA for Revefenacin Inhalation Solution
May 13, 2026
Lupin Receives U.S. FDA Approval for Famotidine Injection, USP
May 5, 2026
Lupin Receives U.S. FDA Approval for Glycerol Phenylbutyrate Oral Liquid
April 22, 2026
Lupin Launches Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the United States
April 10, 2026
Lupin Launches Dapagliflozin Tablets in the United States
April 8, 2026
Lupin Announces Approval of Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the United States
April 7, 2026
Lupin Announces the Approval of Dapagliflozin Tablets in the United States
April 2, 2026
Lupin Completes Acquisition of VISUfarma
March 31, 2026
Lupin Receives Tentative Approval from U.S. FDA for Sugammadex Injection
Media
Rajalakshmi Azariah
Vice President & Global Head - Corporate Communications
rajalakshmiazariah@lupin.comElise Titan
Director, U.S. Communications
elisetitan@lupin.comSmart Guide
Close
CloseSearch Product
Global Privacy Control Detected
We have detected your Global Privacy Control (GPC) signal. In accordance with applicable privacy laws, we have automatically honored your preference and disabled all non-essential cookies and tracking.
Only necessary cookies required for the website to function are enabled.
Opt-Out Request Honored
We have respected your privacy preference. Your opt-out request through cookie settings or Global Privacy Control signal has been honored.